Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia : a randomized trial
© 2023. The Author(s)..
Treatment failure occurs in about 25% of patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. We conducted a multicenter, open-label, phase III-IV superiority randomized clinical trial. We randomly assigned patients (1:1) to receive 2 g of intravenous cloxacillin alone every 4 h or with 3 g of intravenous fosfomycin every 6 h for the initial 7 days. The primary endpoint was treatment success at day 7, a composite endpoint with the following criteria: patient alive, stable or with improved quick Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA, adjudicated by an independent committee blinded to treatment allocation. We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. We analyzed the primary endpoint with the intention-to-treat approach in 214 patients who received at least 1 day of treatment. Treatment success at day 7 after randomization was achieved in 83 (79.8%) of 104 patients receiving combination treatment versus 82 (74.5%) of 110 patients receiving monotherapy (risk difference 5.3%; 95% confidence interval (CI), -5.95-16.48). Secondary endpoints, including mortality and adverse events, were similar in the two groups except for persistent bacteremia at day 3, which was less common in the combination arm. In a prespecified interim analysis, the independent committee recommended stopping recruitment for futility prior to meeting the planned randomization of 366 patients. Cloxacillin plus fosfomycin did not achieve better treatment success at day 7 of therapy than cloxacillin alone in MSSA bacteremia. Further trials should consider the intrinsic heterogeneity of the infection by using a more personalized approach. ClinicalTrials.gov registration: NCT03959345.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 10 vom: 02. Okt., Seite 2518-2525 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 13.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT03959345 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02569-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362797501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362797501 | ||
| 003 | DE-627 | ||
| 005 | 20231226092005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02569-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362797501 | ||
| 035 | |a (NLM)37783969 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grillo, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia |b a randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03959345 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Treatment failure occurs in about 25% of patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. We conducted a multicenter, open-label, phase III-IV superiority randomized clinical trial. We randomly assigned patients (1:1) to receive 2 g of intravenous cloxacillin alone every 4 h or with 3 g of intravenous fosfomycin every 6 h for the initial 7 days. The primary endpoint was treatment success at day 7, a composite endpoint with the following criteria: patient alive, stable or with improved quick Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA, adjudicated by an independent committee blinded to treatment allocation. We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. We analyzed the primary endpoint with the intention-to-treat approach in 214 patients who received at least 1 day of treatment. Treatment success at day 7 after randomization was achieved in 83 (79.8%) of 104 patients receiving combination treatment versus 82 (74.5%) of 110 patients receiving monotherapy (risk difference 5.3%; 95% confidence interval (CI), -5.95-16.48). Secondary endpoints, including mortality and adverse events, were similar in the two groups except for persistent bacteremia at day 3, which was less common in the combination arm. In a prespecified interim analysis, the independent committee recommended stopping recruitment for futility prior to meeting the planned randomization of 366 patients. Cloxacillin plus fosfomycin did not achieve better treatment success at day 7 of therapy than cloxacillin alone in MSSA bacteremia. Further trials should consider the intrinsic heterogeneity of the infection by using a more personalized approach. ClinicalTrials.gov registration: NCT03959345 | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Clinical Trial, Phase IV | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Cloxacillin |2 NLM | |
| 650 | 7 | |a O6X5QGC2VB |2 NLM | |
| 650 | 7 | |a Fosfomycin |2 NLM | |
| 650 | 7 | |a 2N81MY12TE |2 NLM | |
| 650 | 7 | |a Methicillin |2 NLM | |
| 650 | 7 | |a Q91FH1328A |2 NLM | |
| 700 | 1 | |a Pujol, Miquel |e verfasserin |4 aut | |
| 700 | 1 | |a Miró, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a López-Contreras, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Euba, Gorane |e verfasserin |4 aut | |
| 700 | 1 | |a Gasch, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Boix-Palop, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-País, Maria José |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Rodríguez, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez-Zorrilla, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Oriol, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a López-Cortés, Luis Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Pedro-Botet, Maria Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a San-Juan, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Gioia, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Iftimie, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Morata, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Jover-Sáenz, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Pardo, Graciano |e verfasserin |4 aut | |
| 700 | 1 | |a Loeches, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Izquierdo-Cárdenas, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Goikoetxea, Ane Josune |e verfasserin |4 aut | |
| 700 | 1 | |a Gomila-Grange, Aina |e verfasserin |4 aut | |
| 700 | 1 | |a Dietl, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Berbel, Damaris |e verfasserin |4 aut | |
| 700 | 1 | |a Videla, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Hereu, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Padullés, Ariadna |e verfasserin |4 aut | |
| 700 | 1 | |a Pallarès, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Tebé, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Cuervo, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Carratalà, Jordi |e verfasserin |4 aut | |
| 700 | 0 | |a SAFO study group |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Maria Alba |e investigator |4 oth | |
| 700 | 1 | |a Aguirregabiria, Malen |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Álvarez, Regino |e investigator |4 oth | |
| 700 | 1 | |a Blanco-Vidal, María José |e investigator |4 oth | |
| 700 | 1 | |a Alguacil-Guillen, Marina |e investigator |4 oth | |
| 700 | 1 | |a Xercavins, Mariona |e investigator |4 oth | |
| 700 | 1 | |a Pomar, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Siverio-Parés, Ana |e investigator |4 oth | |
| 700 | 1 | |a de Cueto, Marina |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Mellado, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Sousa, Adrián |e investigator |4 oth | |
| 700 | 1 | |a Vasallo-Vidal, Francisco José |e investigator |4 oth | |
| 700 | 1 | |a Borjabad, Beatriz |e investigator |4 oth | |
| 700 | 1 | |a Coloma-Conde, Ana |e investigator |4 oth | |
| 700 | 1 | |a Clivillé-Abad, Raquel |e investigator |4 oth | |
| 700 | 1 | |a González-di Lauro, Sabina Ximena |e investigator |4 oth | |
| 700 | 1 | |a Tiago-Silva, Jose |e investigator |4 oth | |
| 700 | 1 | |a Orellana, Maria Angeles |e investigator |4 oth | |
| 700 | 1 | |a Ruíz-Bastián, Mario |e investigator |4 oth | |
| 700 | 1 | |a Vizcarra, Pilar |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Carles |e investigator |4 oth | |
| 700 | 1 | |a Ballester, Frédéric |e investigator |4 oth | |
| 700 | 1 | |a Ramírez-Hidalgo, María Fernanda |e investigator |4 oth | |
| 700 | 1 | |a Bellés-Bellés, Alba |e investigator |4 oth | |
| 700 | 1 | |a Meije, Yolanda |e investigator |4 oth | |
| 700 | 1 | |a Ribera, Alba |e investigator |4 oth | |
| 700 | 1 | |a LLaberia, Jaume |e investigator |4 oth | |
| 700 | 1 | |a Domínguez, María Ángeles |e investigator |4 oth | |
| 700 | 1 | |a Rigo-Bonnin, Raul Francisco |e investigator |4 oth | |
| 700 | 1 | |a Horna, Gertrudis |e investigator |4 oth | |
| 700 | 1 | |a Mediavilla, Dominica |e investigator |4 oth | |
| 700 | 1 | |a Sanllorente, Mireia |e investigator |4 oth | |
| 700 | 1 | |a Picó-Plana, Ester |e investigator |4 oth | |
| 700 | 1 | |a Soriano, Alex |e investigator |4 oth | |
| 700 | 1 | |a Pitart, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Sanchez-Diaz, Ana Maria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 10 vom: 02. Okt., Seite 2518-2525 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:10 |g day:02 |g month:10 |g pages:2518-2525 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02569-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 10 |b 02 |c 10 |h 2518-2525 | ||